Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29756083 | 0.84 | CYP3A4 (0.52) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL13064827 | 0.82 | CA12 (0.50) | CA12CA7CA9CA14LMNA | |
| SCHEMBL28160684 | 0.81 | HDAC3 (0.47) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL27764678 | 0.81 | CA12 (0.46) | CA12CA7CA9CA14LMNA | |
| SCHEMBL11121883 | 0.81 | PPARG (0.50) | CA12CA7CA9CA14LMNA | |
| SCHEMBL16728552 | 0.81 | CA12 (0.46) | CA12CA7CA9CA14LMNA | |
| SCHEMBL18329328 | 0.81 | CA12 (0.46) | CA12CA7CA9CA14LMNA | |
| SCHEMBL28556129 | 0.80 | LMNA (0.51) | CA12CA7CA9CA14LMNA | |
| SCHEMBL9344234 | 0.80 | KCNA5 (0.54) | CA12CA7CA9CA14TSHR | |
| SCHEMBL11375764 | 0.79 | PPARG (0.54) | CA12CA7CA9CA14LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267628-A1 | ISOMER-SELECTIVE SYNTHESIS OF METHANOFULLERENES | NANO-C, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170267628-A1 | ISOMER-SELECTIVE SYNTHESIS OF METHANOFULLERENES | NANO-C, INC. | 2017-09-21 | — | — | US | disclosed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9527797-B1 | Isomer-selective synthesis of methanofullerenes | NANO-C, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527797-B1 | Isomer-selective synthesis of methanofullerenes | NANO-C, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| CN-103052636-B | D 2antagonist and synthetic method thereof and using method | Altos Therapeutics, LLC (US) | 2016-03-09 | — | — | CN | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| EP-2582701-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| CN-103052636-A | D2 antagonists, methods of synthesis and methods of use | ALTOS THERAPEUTICS LLC | 2013-04-17 | — | — | CN | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
| WO-2011160084-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | CA12 3253/4885CA7 3624/4885CA9 3953/4885 |
| US-20170267628-A1 | ISOMER-SELECTIVE SYNTHESIS OF METHANOFULLERENES | GABRB1, GABRB3, GABRB2 | CA12 2705/4885CA7 1306/4885CA9 2308/4885 |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | CA12 3253/4885CA7 3624/4885CA9 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.